This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Ekso Bionics Holdings (EKSO) Aperçu de l'action
Ekso Bionics Holdings, Inc. conçoit, développe, distribue et commercialise des produits d'exosquelette en Amérique, en Europe, au Moyen-Orient, en Afrique, en Asie-Pacifique et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
EKSO Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ekso Bionics Holdings, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$11.80 |
| Plus haut sur 52 semaines | US$13.50 |
| Plus bas sur 52 semaines | US$2.73 |
| Bêta | 0.78 |
| Variation sur 1 mois | 25.53% |
| Variation sur 3 mois | 30.10% |
| Variation sur 1 an | 65.13% |
| Variation sur 3 ans | -49.89% |
| Variation sur 5 ans | -84.70% |
| Évolution depuis l'introduction en bourse | -99.68% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Apr 23
EKSO: Going Concern Warning Will Drive Bearish Outlook On Shares
Analysts have maintained their $9.50 price target for Ekso Bionics Holdings, noting that only modest adjustments were made to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major change to the overall investment case. What's in the News Auditor WithumSmith+Brown, PC issued an unqualified opinion in the 10-K filed on February 23, 2026, while also expressing doubt about Ekso Bionics Holdings' ability to continue as a going concern, highlighting liquidity and sustainability questions for shareholders (Key Developments).Mise à jour du récit • Apr 09
EKSO: Going Concern Risk And Capital Raises Will Shape Balanced Outlook
Analysts have kept their $9.50 price target for Ekso Bionics Holdings unchanged, pointing to only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the reason for holding steady. What's in the News Filed Form 10-K for the year ended December 31, 2025, with auditor WithumSmith+Brown, PC issuing an unqualified opinion that includes doubt about Ekso Bionics Holdings continuing as a going concern (10-K filing).Mise à jour du récit • Mar 25
EKSO: Reverse Merger And Going Concern Risk Will Drive Bearish Outlook
Analysts have modestly adjusted their price target for Ekso Bionics Holdings, citing small updates to inputs such as the discount rate, an assumed long term revenue growth rate of about 33.71%, and a future P/E assumption of about 43.20x. Taken together, these inputs leave their view of fair value steady at $9.50 per share.Recent updates
Mise à jour du récit • Apr 23
EKSO: Going Concern Warning Will Drive Bearish Outlook On Shares
Analysts have maintained their $9.50 price target for Ekso Bionics Holdings, noting that only modest adjustments were made to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major change to the overall investment case. What's in the News Auditor WithumSmith+Brown, PC issued an unqualified opinion in the 10-K filed on February 23, 2026, while also expressing doubt about Ekso Bionics Holdings' ability to continue as a going concern, highlighting liquidity and sustainability questions for shareholders (Key Developments).Mise à jour du récit • Apr 09
EKSO: Going Concern Risk And Capital Raises Will Shape Balanced Outlook
Analysts have kept their $9.50 price target for Ekso Bionics Holdings unchanged, pointing to only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the reason for holding steady. What's in the News Filed Form 10-K for the year ended December 31, 2025, with auditor WithumSmith+Brown, PC issuing an unqualified opinion that includes doubt about Ekso Bionics Holdings continuing as a going concern (10-K filing).Mise à jour du récit • Mar 25
EKSO: Reverse Merger And Going Concern Risk Will Drive Bearish Outlook
Analysts have modestly adjusted their price target for Ekso Bionics Holdings, citing small updates to inputs such as the discount rate, an assumed long term revenue growth rate of about 33.71%, and a future P/E assumption of about 43.20x. Taken together, these inputs leave their view of fair value steady at $9.50 per share.Mise à jour du récit • Mar 11
EKSO: Reverse Merger Uncertainty Will Drive Bearish Long Term Outlook
Analysts have nudged their price target on Ekso Bionics Holdings higher to $9.50 per share, reflecting updated assumptions around revenue growth, profit margin and a lower forward P/E. Together, these factors support a stronger long term valuation case at the same fair value estimate of $9.50.Mise à jour du récit • Feb 24
EKSO: Reverse Merger And Revenue Slowdown Will Shape Cautious Outlook
Analysts have maintained their $9.50 price target on Ekso Bionics Holdings, citing only minor adjustments to inputs such as the discount rate, long term revenue growth assumptions, profit margin and future P/E that do not materially alter their valuation view. What’s in the News Applied Digital Cloud Corporation signed a letter of intent to acquire Ekso Bionics Holdings in a reverse merger, with Applied Digital expected to own about 97% of the combined company.Mise à jour du récit • Feb 10
EKSO: Q3 Sales Recovery And Business Review Will Shape Balanced Outlook
Analysts have lifted their price target on Ekso Bionics Holdings to US$6 from US$4, citing a solid Q3 update and a company-led review of its current business as key supports for the revised valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$6 price target as a reflection of increased confidence in the company’s ability to execute on its current business plan following the Q3 update.Mise à jour du récit • Jan 27
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Narrative Update Analysts have lifted their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 report, a newly announced review of the current business, and signs that earlier order delays may have been specific to prior periods rather than ongoing. Analyst Commentary Analysts raising their price target to $6 from $4 are reacting to the recent Q3 report and the announced review of the current business, while still flagging a few key execution risks that could affect how the story plays out from here.Mise à jour du récit • Jan 12
EKSO: Q3 Sales Recovery And Business Review Will Support Future Upside
Analysts have lifted their fair value estimate for Ekso Bionics Holdings from $7.75 to $9.50, citing a higher Street price target of $6.00, a solid Q3 report, and the ongoing review of the current business as key reasons for the reassessment. Analyst Commentary Recent Street research reflects a mix of optimism and caution around Ekso Bionics Holdings, with the latest price target move to US$6 framed around the recent Q3 report and the ongoing review of the current business.Mise à jour du récit • Dec 26
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Analysts have modestly raised their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 performance and signs that earlier order delays were idiosyncratic, even as they await further confirmation that the recent sales recovery is sustainable. Analyst Commentary Bullish analysts view the higher price target as a reflection of improving execution and a clearer path to value creation following the strong Q3 report and strategic review announcement.Article d’analyse • Dec 23
Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Shares Bounce 29% But Its Business Still Trails The Industry
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a really impressive month, gaining 29% after a shaky period...
Mise à jour du récit • Dec 12
EKSO: Q3 Sales Momentum Is Expected To Drive Shares Higher
Analysts have raised their price target on Ekso Bionics Holdings to $6.00 from $4.00, citing stronger than expected Q3 sales momentum, a modestly lower perceived risk profile, and improved long term growth and profitability assumptions. Analyst Commentary Bearish analysts acknowledge that the higher price target reflects a solid Q3, but emphasize that the implied upside is increasingly reliant on sustained execution against a still-early sales recovery.Mise à jour du récit • Nov 27
EKSO: Sales Recovery and Increased Confidence Will Drive Future Stock Performance
Analysts have raised their price target for Ekso Bionics from $6.75 to $7.75. This change reflects stronger revenue growth expectations and a solid recent earnings report.Article d’analyse • Aug 24
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 26% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...Mise à jour du récit • Aug 10
Advanced Exoskeleton Devices Will Broaden Rehabilitation Market Access
The drastic reduction in Ekso Bionics Holdings' consensus price target from $34.75 to $6.75 reflects sharply lower growth and earnings expectations as seen in the substantial drop in its forward P/E multiple from 24.94x to 4.86x. What's in the News Launched eksoUniversity, an online platform offering CEU-approved courses for physical therapists and assistants in over 30 states.Article d’analyse • Jun 22
Not Many Are Piling Into Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Stock Yet As It Plummets 31%
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 31% in the...Article d’analyse • Jun 22
Slammed 31% Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares are down a considerable 31...
Nouveau récit • May 01
PRIA Healthcare And National Seating Will Streamline Medicare Claims
Strategic partnerships aim to broaden distribution, streamline reimbursements, and enhance revenue growth in the personal health market.Article d’analyse • Mar 07
It's Down 27% But Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Could Be Riskier Than It Looks
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 27% in the...Article d’analyse • Mar 06
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), who've watched their investment drop 17% to...Article d’analyse • Jan 12
Even With A 39% Surge, Cautious Investors Are Not Rewarding Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Performance Completely
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders are no doubt pleased to see that the share price has bounced...Article d’analyse • Nov 12
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders that were waiting for something to happen have been dealt a...Article d’analyse • Aug 29
Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...Article d’analyse • Jul 13
Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a buy...Article d’analyse • May 02
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00
It's shaping up to be a tough period for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), which a week ago released some...Article d’analyse • Dec 20
Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) is a...Article d’analyse • Jun 19
Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong...Rendement pour les actionnaires
| EKSO | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | 3.8% | -2.7% | 0.8% |
| 1Y | 65.1% | -20.6% | 20.5% |
Rendement vs Industrie: EKSO a dépassé le secteur US Medical Equipment qui a rapporté -20.6 % au cours de l'année écoulée.
Rendement vs marché: EKSO a dépassé le marché US qui a rapporté 20.5 % au cours de l'année écoulée.
Volatilité des prix
| EKSO volatility | |
|---|---|
| EKSO Average Weekly Movement | 12.3% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de EKSO a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de EKSO a diminué de 19% à 12% au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2005 | 53 | Scott Davis | www.eksobionics.com |
Ekso Bionics Holdings, Inc. conçoit, développe, distribue et commercialise des produits d'exosquelette en Amérique, en Europe, au Moyen-Orient, en Afrique, en Asie-Pacifique et dans le monde entier. La société propose EksoNR, un exosquelette robotique portable, Ekso Indego Therapy, un exosquelette motorisé, Ekso Indego Personal, une orthèse motorisée pour les membres inférieurs, et Ekso EVO, un exosquelette portable pour le haut du corps. Elle développe également l'Ekso Nomad, une orthèse de genou-cheville-pied (KAFO) motorisée, et le système de rééducation MediTouch BalanceTutor, un tapis roulant à perturbations multidirectionnelles.
Ekso Bionics Holdings, Inc. Résumé des fondamentaux
| EKSO statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$42.01m |
| Bénéfices(TTM) | -US$15.91m |
| Recettes(TTM) | US$11.57m |
3.6x
Ratio P/S-2.6x
Ratio P/ELe site EKSO est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| EKSO compte de résultat (TTM) | |
|---|---|
| Recettes | US$11.57m |
| Coût des recettes | US$5.45m |
| Marge brute | US$6.11m |
| Autres dépenses | US$22.03m |
| Les revenus | -US$15.91m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -4.47 |
| Marge brute | 52.86% |
| Marge bénéficiaire nette | -137.61% |
| Ratio dettes/capitaux propres | 67.0% |
Quelles ont été les performances à long terme de EKSO?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/04 06:47 |
| Cours de l'action en fin de journée | 2026/05/04 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Ekso Bionics Holdings, Inc. est couverte par 7 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Tom Grady | Edison Investment Research |
| Dan Scovel | Edison Investment Research |